The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
case one is I'm assuming it's ER positive PR agnostic her two new her two negative correct that's correct though the vast vast majority of those tumors also Express progesterone receptor got it um you made the case again these are the ones that are showing up more likely on mamography they're also showing up in older women median age I think said about 65 reasonably across the whole age Spectrum but the peak is 65 and um that's correct yep
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
there are really three major flavors of breast cancer there is estrogen receptor positive so-called her2 or hr2 negative breast cancers and those are the most prevalent kinds of breast cancer um they account for 70 to 75% if not more of all breast cancers they are the tumors most likely to be found on screening mamography as opposed to presenting with a lump in the breast they tend to have ounce f size for size the most favorable prognosis in most but not all instances
of all breast cancers they are the tumors most likely to be found on screening mamography as opposed to presenting with a lump in the breast they tend to have ounce for ounce size for size the most favorable prognosis in most but not all instances and um they peak in incidents at around age 65 in the United States so that is the sort of Public Health face of a lot of breast cancer
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.